Testing BI 764198 in adults and teens with kidney disease
Part of Kidney & urinary clinical trials.
This study tests an investigational drug (BI 764198) in adults and teens with different types of kidney disease. The goal is to see if the drug can help slow kidney damage. You may be able to join if your kidney function is at a certain level, you are on stable blood pressure medications, and you haven't had recent strong immune treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old (or at least 12 if you have a specific type of kidney disease called treatment‑resistant primary minimal change disease).
- Your kidney function (eGFR) must be 25 or higher — this is a number your doctor can check.
- You must be taking a stable dose of a blood pressure medication called an ACE inhibitor or ARB for at least 8 weeks (or be on stable doses of other common kidney meds like SGLT2 inhibitors).
- If you take other immunosuppressant pills (not steroids), you must be on a steady dose for at least 12 weeks.
- You cannot have had an organ transplant, and you cannot have received certain strong immune‑suppressing drugs through an IV in the last 6 months.
- You cannot be taking metformin or some other specific medications within a week of starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
This trial tests how safe and tolerable different doses of the study drug BI 3814916 are in healthy adults. It helps find the right dose for future studies.
This study tests how a new experimental drug (INCB123667) works and is tolerated in adults with severe kidney problems or end-stage kidney disease. Researchers want to understand how the drug moves through the body and whether it's safe for people in your situation.
This study tests a new medicine (BI 3776528) in healthy men to see how well different doses are tolerated. It helps researchers find the safest dose before testing in people with a condition.
Hear when a new Proteinuric Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.